Raymond James & Associates Olink Holding Ab (Publ) Transaction History

Raymond James & Associates

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	SELL	$14.45 - $20.34 $10,736 - $15,112	-743 Reduced 4.21%	16,921 $249,000
Q2 2023 Jul 25, 2023	SELL	$17.13 - $23.74 $2,226 - $3,086	-130 Reduced 0.73%	17,664 $331,000
Q1 2023 Apr 14, 2023	SELL	$19.34 - $24.11 $74,478 - $92,847	-3,851 Reduced 17.79%	17,794 $400,000
Q4 2022 Feb 08, 2023	BUY	$12.64 - $25.52 $124,377 - $251,116	9,840 Added 83.35%	21,645 $549,000
Q3 2022 Oct 25, 2022	BUY	$12.14 - $18.42 $2,695 - $4,089	222 Added 1.92%	11,805 $143,000

Q2 2022 Aug 12, 2022	SELL	$8.95 - $19.24 $2,049 - $4,405	-229 Reduced 1.94%	11,583 $176,000
Q1 2022 May 11, 2022	BUY	$11.33 - $19.3 $133,829 - $227,971	11,812 New	11,812 $209,000
Q4 2021 Feb 08, 2022	SELL	$18.0 - $34.82 $158,328 - $306,276	-8,796 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$23.42 - $37.93 $11,405 - $18,471	487 Added 5.86%	8,796 $213,000
Q2 2021 Aug 11, 2021	BUY	$26.65 - $39.47 $221,434 - $327,956	8,309 New	8,309 $286,000

38.1M

52.2K

134K

Ticker OLK
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 119,098,000
Market Cap $3.1B
Description
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.